New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Mark Neumann Biography and Net Worth

EVP of Intra-Cellular Therapies

Mr. Neumann joined the Company as Executive Vice President and Chief Commercial Officer in October 2018. Mr. Neumann has over 30 years of biopharmaceutical industry experience with a strong track record of building high-performing commercial teams and successfully executing numerous product launches across a range of therapeutic areas. Mark joined ITCI from Amgen where he was initially recruited as Vice President, Marketing to build and establish a new U.S. cardiovascular business unit, and launch Amgen’s first ever cardiovascular medicines. In his most recent role as Vice President, Global Marketing with leadership of nephrology, inflammation, and bone health, Mr. Neumann was responsible for conceiving therapeutic area strategies, developing marketing platforms for global launches and directing commercial assessments for external business development opportunities. He was initially recruited at Amgen as Vice President, Marketing to build and establish a new U.S. cardiovascular business unit, and launch Amgen’s first ever cardiovascular medicine.

Prior to Amgen, Mr. Neumann spent 25 years at Bristol-Myers Squibb (BMS) and held senior U.S. and global commercial roles in neuroscience, cardiovascular and diabetes. During his tenure at BMS he led sales and marketing for the U.S. neuroscience business unit, and delivered strong growth of the antipsychotic aripiprazole. He also held the position of Vice President, Global Commercialization for neuroscience where he established a new worldwide disease area strategy and directed the commercialization of neuroscience pipeline assets.

Mark received his Bachelor of Arts in Economics and Business Administration degree from Lafayette College.

What is Mark Neumann's net worth?: The estimated net worth of Mark Neumann is at least $2.51 million as of August 16th, 2024. Mr. Neumann owns 29,700 shares of Intra-Cellular Therapies stock worth more than $2,509,947 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Neumann may own. Additionally, Mr. Neumann receives an annual salary of $998,360.00 as EVP at Intra-Cellular Therapies. Learn More about Mark Neumann's net worth.
How old is Mark Neumann?: Mr. Neumann is currently 61 years old. There are 6 older executives and no younger executives at Intra-Cellular Therapies. The oldest executive at Intra-Cellular Therapies is Dr. Robert E. Davis Ph.D., Senior VP & Chief Scientific Officer, who is 73 years old. Learn More on Mark Neumann's age.
What is Mark Neumann's salary?: As the EVP of Intra-Cellular Therapies, Inc., Mr. Neumann earns $998,360.00 per year. The highest earning executive at Intra-Cellular Therapies is Dr. Sharon Mates Ph.D., Co-Founder, Chairman & CEO, who commands a salary of $2,230,000.00 per year. Learn More on Mark Neumann's salary.
How do I contact Mark Neumann?: The corporate mailing address for Mr. Neumann and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Mark Neumann's contact information.
Has Mark Neumann been buying or selling shares of Intra-Cellular Therapies?: Mark Neumann has not been actively trading shares of Intra-Cellular Therapies over the course of the past ninety days. Most recently, Mark Neumann sold 18,714 shares of the business's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $75.08, for a transaction totalling $1,405,047.12. Following the completion of the sale, the executive vice president now directly owns 29,700 shares of the company's stock, valued at $2,229,876. Learn More on Mark Neumann's trading history.
Who are Intra-Cellular Therapies' active insiders?: Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.
Are insiders buying or selling shares of Intra-Cellular Therapies?: During the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 667,956 shares worth more than $46,911,949.27. The most recent insider tranaction occured on November, 12th when President Michael Halstead sold 22,869 shares worth more than $2,038,085.28. Insiders at Intra-Cellular Therapies own 2.6% of the company. Learn More about insider trades at Intra-Cellular Therapies.
Information on this page was last updated on 11/12/2024.

Mark Neumann Insider Trading History at Intra-Cellular Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2024	Sell	18,714	$75.08	$1,405,047.12	29,700
11/6/2023	Sell	42,393	$55.63	$2,358,322.59	29,700
8/7/2023	Sell	55,300	$58.79	$3,251,087.00	45,339
3/28/2023	Sell	15,604	$54.31	$847,453.24	45,339
3/10/2023	Sell	8,550	$43.34	$370,557.00	57,357
3/1/2023	Sell	7,241	$50.01	$362,122.41	49,199
2/24/2023	Sell	4,046	$47.12	$190,647.52	56,440
2/21/2023	Sell	3,898	$47.01	$183,244.98	52,580
4/8/2022	Sell	86,348	$64.37	$5,558,220.76	45,339
2/24/2022	Sell	7,906	$52.21	$412,772.26
2/22/2022	Sell	11,139	$55.29	$615,875.31
1/10/2022	Sell	20,948	$40.78	$854,259.44
10/18/2021	Sell	13,448	$40.86	$549,485.28
2/19/2021	Sell	5,184	$39.22	$203,316.48	50,523
1/11/2021	Sell	9,684	$32.02	$310,081.68	49,068
10/16/2020	Sell	6,792	$26.80	$182,025.60	34,912
10/16/2019	Sell	6,774	$8.25	$55,885.50	13,448

Mark Neumann Buying and Selling Activity at Intra-Cellular Therapies

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $84.51

$84.51

$86.00

50 Day Range

MA: $78.84

$71.19

$91.57

2 Week Range

Now: $84.51

$58.14

$93.45

Volume

31,590 shs

Average Volume

856,425 shs

Market Capitalization

$8.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

From Darwin | Ad

👉 Click here to access your FREE report now!

Mark Neumann Biography and Net Worth

What is Mark Neumann's net worth?

How old is Mark Neumann?

What is Mark Neumann's salary?

How do I contact Mark Neumann?

Has Mark Neumann been buying or selling shares of Intra-Cellular Therapies?

Who are Intra-Cellular Therapies' active insiders?

Are insiders buying or selling shares of Intra-Cellular Therapies?